MedTrace Logo

Hepatic Artery Infusion Pump for NPC Liver Metastases

NCT03876574 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-03-15

No results posted yet for this study

Summary

A retrospective clinical trial to study the safety and effectiveness of hepatic arterial infusion (HAI) in treating patients who have nasopharyngeal carcinoma metastatic to the liver. Hepatic-direction drug administration improves the control power for intra-hapatic lesions.

Conditions

  • Nasopharyngeal Carcinoma
  • Neoplasm Metastasis
  • Liver

Interventions

PROCEDURE

DSA-guided implantation of hepatic artery infusion pump

Implant the infusion catheter and injection port (Celsite, B. Braun, Chasseneuil, France) under DSA-guiding. The proximal end of the infusion catheter was connected to the injection port and the device was implanted in a subcutaneous pocket in the right inner thigh; the distal end of the infusion catheter guarantee uni-direction infusion to liver.

DRUG

Gemcitabine

Given intra-arterially for 30 minutes

DRUG

Floxuridine

Given intra-arterially continuously for 14 days

DRUG

dexamethasone

Given intra-arterially continuously with 5-FUDR

Sponsors & Collaborators

  • Xiangya Hospital of Central South University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2017-12-31
Completion
2017-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03876574 on ClinicalTrials.gov